Bis(2-oxo-3-oxazolidinyl)phosphine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: Bis(2-oxo-3-oxazolidinyl)phosphine
• 英文别名: 3-[(2-oxo-1,3-oxazolidin-3-yl)phosphanyl]-1,3-oxazolidin-2-one
• 化学式: C₆H₉N₂O₄P
• 分子量: 204.12
• InChiKey: SEOZPKYDFRZJMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS TRICYCLIQUES DE GYRASE UTILISABLES COMME AGENTS ANTIBACTÉRIENS
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2014043272A1

  公开（公告）日：2014-03-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有化学式I结构的化合物及其药用盐、酯和前药，这些化合物可用作抗菌有效的三环酶抑制剂。此外，本文还披露了三环酶抑制剂化合物的种属。还考虑了相关的药用组合物、用途和制备这些化合物的方法。
• Controlled drug delivery system using the conjugation of drug to biodegradable polyester
  申请人：——

  公开号：US20040013728A1

  公开（公告）日：2004-01-22

  The present invention relates to the molecular sustained controlled release system constructed by the conjugation of molecules to be released with biodegradable polyester polymer via covalent bond and method for preparation thereof. In accordance with the present invention, the system may be formulated into microspheres, nanoparticles, or films. The molecular release rate from the above system can be regulated to be proportional to the chemical degradation rate of the biodegradable polyester polymers, resulting in near zero order kinetics profile of release without showing a burst effect. Moreover, the high loading efficiency of hydrophilic drugs can be achieved.

  本发明涉及通过共价键将待释放的分子与可生物降解聚酯聚合物结合而构建的分子持续控释系统，以及其制备方法。根据本发明，该系统可以制备成微球、纳米颗粒或薄膜。上述系统中的分子释放速率可以调节为与可生物降解聚酯聚合物的化学降解速率成比例，从而导致释放近似零级动力学剖面而不显示爆发效应。此外，可以实现亲水药物的高装载效率。
• TRICYCLIC GYRASE INHIBITORS
  申请人：Bensen Daniel

  公开号：US20120238751A1

  公开（公告）日：2012-09-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有式I结构的化合物，以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药，相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
• [EN] SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS<br/>[FR] DERIVES DE PYRROLE SUBSTITUES UTILES COMME INHIBITEURS DE HMG-COA REDUCTASE
  申请人：RANBAXY LAB LTD

  公开号：WO2004105752A1

  公开（公告）日：2004-12-09

  The present invention relates to substituted pyrrole derivatives of Formula (I), wherein (Y), with the proviso that one of R2, R4 and R5 is a heterocycle and with the further provision that if R2 is not a heterocycle then either R4 or R5 alone is not unsubstituted pyridyl, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

  本发明涉及式（I）的取代吡咯衍生物，其中（Y），条件是R2、R4和R5中的一个是杂环，并且进一步规定如果R2不是杂环，则R4或R5中的任一者不是未取代的吡啶基，这些衍生物可用作3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂。本文披露的化合物可以作为降低胆固醇的药剂，并可用于治疗与胆固醇相关的疾病及相关症状。提供了用于制备披露的化合物的方法，以及含有披露的化合物的药物组合物和治疗与胆固醇相关的疾病及相关症状的方法。
• [EN] PROCESS FOR THE PREPARATION OF ATORVASTATIN<br/>[FR] PROCEDE DE PREPARATION D'ATORVASTATINE
  申请人：RANBAXY LAB LTD

  公开号：WO2005118536A1

  公开（公告）日：2005-12-15

  The invention relates to processes for the preparation of atorvastatin. Atorvastatin is known by the chemical name [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid. The hemi-calcium salt of atorvastatin is useful as an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). The invention also relates to pharmaceutical compositions that include the atorvastatin or a pharmaceutically acceptable salt thereof and to use of said compositions for treating hypolipidemia, hypocholesterolemia and atherosclerosis.

  本发明涉及阿托伐他汀的制备过程。阿托伐他汀的化学名称为[R-(R*，R*)]-2-(4-氟苯基)-β，δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯氨基)羰基]-1H-吡咯烷-1-庚酸。阿托伐他汀的半钙盐可用作3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-CoA还原酶）的抑制剂。本发明还涉及包括阿托伐他汀或其药学上可接受的盐的制药组合物，并且涉及使用该组合物治疗低脂血症、低胆固醇血症和动脉硬化的方法。